Precimmo

Precimmo is a precision oncology company advancing early cancer detection and AI-guided clinical decision support. Our goal is to reduce the cost of cancer care through earlier diagnosis, faster decision-making, more effective therapies, and improved patient survival by lowering relapse rates. Our platform, OncoAdvisor, integrates genomic, epigenetic, and clinical data to recommend the most appropriate diagnostics, treatments, and clinical trials, following global guidelines such as NCCN, ESMO, and ASCO. OncoAdvisor is paired with early cancer detection tools that are CE-IVD, and FDA approved, capable of detecting over 8 cancer types from a single blood test, with clinically proven accuracy of over 90%. Clinicians can input patient data and receive integrated diagnostic and therapeutic recommendations. We are committed to making cancer care more proactive, data driven, and accessible.